PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway
Biochemical Pharmacology · 2025-12 · 242 · 117445
DOI: 10.1016/j.bcp.2025.117445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025-12. Verfasst von Feiye Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Department of The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Fuoshan, Guangdong 528042, China; …. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Transaminases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Prostaglandin F2 receptor negative regulator (PTGFRN) is a transmembrane protein that has been linked to the metastatic behavior of certain cancers. However, its specific function and underlying regulatory mechanisms in lung cancer remain unclear. In this research, we observed that PTGFRN expression was markedly increased in lung cancer tissues compared to normal tissues, and patients with high PTGFRN levels exhibited poorer survival outcomes. Silencing PTGFRN significantly inhibited non-small cell lung cancer cell proliferation, tumor formation, and metastatic capacity. Mechanistically, PTGFRN was found to interact with signal transducer and activator of transcription 3 (STAT3)and inhibit its degradation. The resulting accumulation of STAT3 enhanced its binding to the BCAT1 gene promoter, thereby boosting branched-chain amino acid transaminase 1 (BCAT1) expression. This subsequently elevated branched-chain amino acid (BCAA) metabolism in lung cancer cells. Overall, our findings highlight the tumor-promoting role of PTGFRN in non-small cell lung cancer and demonstrate that PTGFRN accelerates cancer progression by enhancing the STAT3/BCAT1 signaling axis and reprogramming BCAA metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Department of The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Fuoshan, Guangdong 528042, China; Oncology Center of The Sixth Affiliated Hospital, School of Medicine,…
- Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China; Institute of Cancer Stem Cell,DalianMedical University,Dalian, Liaoning 116044, China.
- Institute of Cancer Stem Cell,DalianMedical University,Dalian, Liaoning 116044, China.
- Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian 116021, China. Electronic address: tiansinuo1986@126.com.
- Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China. Electronic address: shendachuan@dlu.edu.cn.
- Respiratory Department of The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Fuoshan, Guangdong 528042, China. Electronic address: 836617041@qq.com.
Zitieren
APA
Liu, F., Li, M., Yu, P., Han, C., Tian, L., Shen, D., & Song, J. (2025). PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway. Biochemical Pharmacology, 242, 117445. https://doi.org/10.1016/j.bcp.2025.117445
Vancouver
Liu F, Li M, Yu P, Han C, Tian L, Shen D, et al. PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway. Biochemical Pharmacology. 2025;242:117445. doi:10.1016/j.bcp.2025.117445
BibTeX
@article{Liu2025,
author = {Liu, Feiye and Li, Mengjie and Yu, Peng and Han, Chuanchun and Tian, Lili and Shen, Dachuan and Song, Jing},
title = {PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway},
journal = {Biochemical Pharmacology},
year = {2025},
volume = {242},
pages = {117445},
doi = {10.1016/j.bcp.2025.117445}
}
EUVIMED